Long-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
“From [the results] of this study, we propose the timing and indication of cytoreductive nephrectomy,” said Hiroshi Kikuchi, MD, PhD.
“Our real-world study showed that PSA response to apalutamide and continuous androgen deprivation therapy was robust and consistent with that in the SPARTAN study,” said Benjamin H. Lowentritt, MD.
